The combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as upfront treatment for non–small cell lung cancer harboring EGFR mutations.
Original Article: Adding Bevacizumab to Erlotinib Prolongs PFS in EGFR-Mutated NSCLC